Views & Analysis Highs and lows in regenerative medicine How developments in gene editing and screening technology are advancing regenerative medicine.
News EU regulators back blood cancer stem cell therapy Molmed's treatment aims to prevent reduce risk of graft-versus-host disease.
News Teva walks away from Mesoblast's heart failure drug Mesoblast to continue developing stem cell based therapy.
News Isomorphic adds MSD to partner roster, and other deals It's been a busy dealmaking week, with Isomorphic Labs, fresh from a $5 billion financing, adding MSD to its list of research alliances.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.